CN106518708B - 新型fxr激动剂的合成和应用 - Google Patents
新型fxr激动剂的合成和应用 Download PDFInfo
- Publication number
- CN106518708B CN106518708B CN201610578225.4A CN201610578225A CN106518708B CN 106518708 B CN106518708 B CN 106518708B CN 201610578225 A CN201610578225 A CN 201610578225A CN 106518708 B CN106518708 B CN 106518708B
- Authority
- CN
- China
- Prior art keywords
- compounds
- yield
- dried
- hours
- organic phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012190 activator Substances 0.000 title claims abstract description 12
- 238000003786 synthesis reaction Methods 0.000 title abstract description 7
- 230000015572 biosynthetic process Effects 0.000 title abstract description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 3
- 208000008589 Obesity Diseases 0.000 claims abstract description 3
- 235000020824 obesity Nutrition 0.000 claims abstract description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 51
- 238000006243 chemical reaction Methods 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 23
- 239000012074 organic phase Substances 0.000 claims description 22
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- 238000010898 silica gel chromatography Methods 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- 239000012043 crude product Substances 0.000 claims description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 6
- 229910002666 PdCl2 Inorganic materials 0.000 claims description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 6
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 claims description 5
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 claims description 5
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 102000001479 Member 11 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 claims description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical class COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical class [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 4
- 235000011152 sodium sulphate Nutrition 0.000 claims description 4
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical class BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 241000400611 Eucalyptus deanei Species 0.000 claims description 3
- 101000978937 Homo sapiens Nuclear receptor subfamily 0 group B member 2 Proteins 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 101001082043 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Translation initiation factor 5A Proteins 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- -1 pinacol borates Chemical class 0.000 claims description 3
- 235000011056 potassium acetate Nutrition 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- JHHMSRLTZAUMOJ-UHFFFAOYSA-N methanamine;oxolane Chemical compound NC.C1CCOC1 JHHMSRLTZAUMOJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 239000002024 ethyl acetate extract Substances 0.000 claims 5
- 238000000605 extraction Methods 0.000 claims 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000012267 brine Substances 0.000 claims 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 2
- 230000006837 decompression Effects 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- GSJRUEBQWPLHSN-UHFFFAOYSA-N n-methylmethanamine;oxolane Chemical compound CNC.C1CCOC1 GSJRUEBQWPLHSN-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract 1
- 102100038495 Bile acid receptor Human genes 0.000 description 26
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VLQTUNDJHLEFEQ-KGENOOAVSA-N Fexaramine Chemical compound COC(=O)\C=C\C1=CC=CC(N(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C)C)C(=O)C2CCCCC2)=C1 VLQTUNDJHLEFEQ-KGENOOAVSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- FWIROFMBWVMWLB-UHFFFAOYSA-N 1-bromo-3-nitrobenzene Chemical class [O-][N+](=O)C1=CC=CC(Br)=C1 FWIROFMBWVMWLB-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
- C07C209/06—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms
- C07C209/10—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms with formation of amino groups bound to carbon atoms of six-membered aromatic rings or from amines having nitrogen atoms bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及化学药物领域。本发明公开了新型FXR激动剂Fex‑3和Fex‑4的合成策略。合成策略步骤简洁,总收率高,可以用于大规模制备。Fex‑3和Fex‑4作为FXR激动剂可以用于治疗胰岛素抵抗和肥胖。
Description
技术领域
本发明涉及新型FXR激动剂的合成和应用,属于化学药物领域。
背景技术
法尼酯受体(FXR)属于核受体家族的一员,作为一种配体激活性转录因子,FXR直接或者间接地参与了超过四十种下游靶基因的转录调控。FXR和人体体内的胆汁酸稳态、糖脂代谢的平衡以及药物的代谢调控和转运有着重要的关系。FXR主要有α和β两种亚型,广泛分布于肝脏、肠道和肾脏等组织器官。FXR参与了体内多条重要的代谢通路,从而对机体的胆汁酸、脂质和糖等的代谢起到调控的作用。除了维持机体胆汁酸稳态、调控糖脂的代谢,FXR对于药物的代谢和转运也有着重要的作用。FXR可以调控多种I相和II相代谢酶和转运体。正常剂量下,对乙酰氨基酚可以通过肝脏的UGT和SULT酶发生葡萄糖醛酸化和硫酸化。但是当剂量过大时,额外的对乙酰氨基酚可以导致肝脏毒性,而FXR可以上调多种II相代谢酶的表达水平,促进药物代谢,起到保肝作用。正因为FXR在机体内的诸多重要作用,FXR被视为是治疗糖尿病、肥胖、肝炎和肝癌等疾病的重要靶点。作为内源性物质胆汁酸的受体,FXR已经成为多种代谢性疾病药物的热门靶点,针对FXR这一靶点已经报道了多种激动剂,包括GW406420,Fexaramine,CDCA22,XL335等。其中,Fexaramine 已经被证实是一种肠道限制性FXR激动剂,可以有效地治疗肥胖和缓解胰岛素抵抗等疾病。
发明内容
本发明所要解决的技术问题是提供新型FXR激动剂的化学合成策略。
本发明为解决上述技术问题所提出的技术方案是:新型FXR激动剂的化学合成策略,包括以下步骤;
(1)4-二甲氨基溴苯(化合物1,10g,49.8mmol)和联硼酸频哪醇酯(16.5g,64.97mmol) 溶于1,4-二氧六环溶液(60ml),加入醋酸钾(12.26g,124.95mmol),PdCl2(dpPf)(1.83g, 2.50mmol),氮气保护,85℃反应4小时后将反应物倒入250ml水中,用乙酸乙酯(50ml×3) 萃取,合并有机相,用饱和氯化铵溶液(100ml×2)洗涤,再用饱和食盐水(100ml)洗涤,加入无水硫酸钠干燥,浓缩后得到棕色胶状粗产品(18g),硅胶柱色谱分离得到化合物2 粗产品(6.5g)。加入石油醚(10ml),抽滤并收集滤饼旋干得到化合物2(5.60g),白色固体,产率45.34%。
(2)3-硝基溴苯(化合物3,10.00g,49.50mmol),丙烯酸甲酯(12.79g,148.51mmol),三乙胺(20.9ml),Pd(OAc)2(222.28mg,0.99mmol)和三苯基膦(519mg,1.98mmol),在 N,N-二甲酰胺(50ml)体系中氮气保护反应18小时。将反应液倒入水(250ml)中,用乙酸乙酯(50ml×3)萃取,合并有机相,用饱和氯化铵溶液(100ml×2)洗涤,无水硫酸钠干燥,旋干溶剂,硅胶柱色谱分离,得到化合物4(5.2g),黄色固体,产率50.7%。
(3)化合物4(5.2g,25.10mmol),锌粉(8.2g,125.49mmol)和氯化铵(6.71g,125.49mmol) 在甲醇-水(50ml,v/v=4∶1)的体系中反应3小时。用饱和碳酸氢钠溶液调pH至8,抽滤,旋干滤液,用乙酸乙酯(50ml×3)萃取剩余物,合并有机相,用饱和食盐水(100ml)洗,无水硫酸钠干燥,抽滤,旋干溶液,得到化合物5粗品(4.25g,,95.56%),黄色固体,产率94.53%。
(4)化合物5(2.5g,14.11mmol)和4-溴苯甲醛(2.61g,14.11mmol)溶于二氯甲烷(30ml) 中,加入乙酸(42.36mg),20℃反应4小时后加入NaBH(OAc)3(4.49g,21.16mmol),10-20℃反应16小时。反应液依次用饱和碳酸氢钠溶液(50ml)、饱和氯化铵溶液(50ml)和饱和食盐水(50ml)洗涤,有机相用无水硫酸钠干燥,过滤出去硫酸钠,有机相浓缩旋干,硅胶柱色谱分离得到化合物6(3.6g),产率73.7%。
(5)化合物6(3.5g,10.11mmol),化合物2(2.75g,11.12mmol),PdCl2(dppf)(369.85mg, 0.505mmol),碳酸钠(3.21g,130.33mmol)溶于1,4-二氧六环-水(50ml,v/v=4∶1)中,氮气保护,85℃反应16小时后将反应液倒入水(80ml)中,用乙酸乙酯(30ml×3)萃取,合并有机相,依次用饱和氯化铵溶液(50ml×2)和饱和食盐水(50ml)洗涤,无水硫酸钠干燥,抽滤旋干,硅胶柱色谱分离,得到化合物7(2.4g),黄色油状,产率61.43%。
(6)化合物7(2.4g,6.21mmol),三乙胺(2.62mL,18.63mmol),4-二甲氨基吡啶(75.87 mg,0.62mmol)溶于二氯甲烷(30ml),10-20℃加入6-溴-2-萘酰氯(1.92g,7.14mmol), 20℃下搅拌反应16小时,硅胶柱色谱分离,得到化合物8(2.2g),黄色固体,产率57.18%。
(7)化合物8(2.2g,3.55mmol),甲胺四氢呋喃溶液(8.88ml,17.75mmol,2M inTHF), Pd(OAc)2(40mg,0.177mmol),碳酸钠(940.9mg,8.88mmol)溶于1,4-二氧六环(50ml)中,氮气保护,100℃下反应16小时后将反应液倒入水(80ml)中,用乙酸乙酯(30ml×3) 萃取,合并有机相,依次用饱和氯化铵溶液(50ml×2)和饱和食盐水(50ml)洗涤,无水硫酸钠干燥,硅胶柱色谱分离得到棕色油状粗产品900mg,使用制备薄层色谱分离得到化合物Fex-4(300mg),产率14.83%,产物为淡黄色固体。1H NMR(300MHz,CDCl3)δ(ppm): 7.69(s,1H),7.59(s,1H),7.42~7.47(m,6H),7.37(d,J=6Hz,1H),7.28~7.31(m,3H),7.08~7.14(m,2H),6.96(d,J=6Hz,1H),6.84~6.86(m,1H),6.72(d,J=6Hz,2H),6.47~6.52(m,2H),6.15(t, J=3Hz,1H),5.14(s,2H),3.64(s,3H),2.87(s,6H),2.68(d,J=3Hz,3H);13C NMR(75MHz,DMSO-d6)δ(ppm):170.05,168.20,166.41,158.43,156.44,149.75,148.98,144.04, 143.67,138.98,135.71,135.17,134.79,129.63,129.26,129.07,128.34,127.65,127.18,126.91, 125.81,125.37,124.81,124.38,118.57,112.58,101.04,52.35,51.46,29.44;HRMS (ESI)m/zcalcd for C37H35N3O3[M+H]+:570.2757;found:570.2663.
采取同样的合成方法,由化合物8制备化合物Fex-4,产率45.11%,淡黄色固体。1HNMR (300MHz,CDCl3)δ(ppm):7.80(s,1H),7.45-7.56(m,6H),7.35-7.38(m,3H),7.27(s,1H), 7.22(d,J=6Hz,1H),7.07-7.13(m,2H),6.97(m,2H),6.77-6.83(m,3H),6.21(d,J=12Hz,1H), 5.19(s,2H),3.75(s,3H),3.01(d,J=8.1Hz,12H);13C NMR(75MHz,DMSO-d6)δ(ppm):170.01, 167.10,166.41,149.74,149.31,143.95,143.65,139.00,135.12,134.99,134.79,129.63,129.24, 129.04,128.41,128.35,127.18,126.91,125.85,125.69,125.37,124.94,124.55,118.57,116.48,112.57,104.91,52.32,51.45,39.99;HRMS(ESI)m/z calcd for C38H37N3O3[M+H]+:584.2913;found 584.2774.
聚合酶链式反应(PCR)验证化合物Fex-3和Fex-4可以激动FXR下游靶基因。具体过程如下:
1.原代肝细胞给药浓度为50μM,给药24h后将细胞板从培养箱中取出,弃去原培养基并用PBS荡洗3次,而后加入1.0ml的RNAiso Plus,吹至液体澄清且无细胞团块,室温静置5min;
2.向上述匀浆裂解液中加入氯仿160μl(RNAiso Plus的1/5体积量),盖紧离心管盖,用手剧烈振荡15s(氯仿沸点低、易挥发,振荡时应小心离心管盖突然弹开)。待溶液充分乳化(无分相现象)后,再室温静置5min。而后于4℃,12000g离心15min。从离心机中小心取出离心管,此时匀浆液分为三层,即:无色的上清液、中间的白色蛋白层及带有颜色的下层有机相。吸取上清液转移至另一新的离心管中(切忌吸出白色中间层)。向上清中加入等体积的异丙醇,上下颠倒离心管充分混匀后,在15~30℃下静置10min。 12000g,4℃离心10min。离心后,试管底部出现白色沉淀,即为总mRNA。
3.小心弃去上清,缓慢地沿离心管壁加入75%的乙醇(DEPC水配制)1.0ml(切勿触及沉淀),轻轻上下颠倒洗涤离心管管壁,于4℃,12000g离心5min后小心弃去乙醇。
4.室温干燥沉淀2-5min(不可以离心或加热干燥,否则RNA将会很难溶解),加入适量的 DEPC水溶解沉淀,必要时可用移液枪轻轻吹打沉淀,待RNA沉淀完全溶解后,定量、逆转录或于-80℃保存。
5.在UV板上,取200μlDEPC水加入空白孔中作为空白对照,其余各孔加入198μlDEPC 水,再分别加入样品Total RNA 2μl,振荡混匀,以全波长荧光酶标仪中测定260nm,280nm,230nm,320nm等波长下的吸光值OD260,OD280,OD230,OD320。按照以下公式计算RNA纯度:RNA纯度=OD260/OD280,该值在1.8-2.2范围内时认为RNA提取纯度较高,且没有降解;按照以下公式计算RNA浓度:RNA浓度=(OD260-OD320)。
6.逆转录
(1)在冰浴环境中配制逆转录反应液,操作参照试剂盒说明书,引物序列如表1所示。
表1PCR引物序列
基因 | 引物序列(正向) | 引物序列(反向) |
FXR | TGGACTCATACAGCAAACAGAGA | GTCTGAAACCCTGGAAGTCTTTT |
SHP | CCTGGAGCAGCCCTCGTCTCAG | AACACTGTATGCAAACCGAGGA |
BSEP | CACTGGCCTTCTGGTATGGT | GCTTGTAGCCGTCTCCTGAC |
CYP7A1 | CAGCCGAGTCCCTTAGCA | CCATCACCGCACAAGAATA |
注:10μl的反应体系可最大使用500ng的Total RNA。
(2)逆转录反应条件
37℃ 15min(反转录反应);
85℃ 5sec(反转录酶的失活反应)。
得到的逆转录反应液(即cDNA溶液)于-20℃保存备用,待Real Time-PCR实验用。
聚合酶链式反应证明本发明中化合物Fex-3和Fex-4可以有效地激动FXR和其下游靶基因SHP、BSEP和CYP7A1。FXR是一种转录因子,可以调控下游多种基因,其中就包括了SHP、BSEP和CYP7A1。激动FXR可以下调CYP7A1的表达,上调SHP和BSEP基因的表达可以作为FXR的激动剂。
附图说明:
图1是新型FXR激动剂Fex-3和Fex-4的合成路线。
图2是Fex-3、Fex-4和Fex(fexaramine)对FXR及其下游靶基因表达水平的影响。
Claims (3)
1.两种FXR激动剂的制备方法,所述方法按如下反应式进行:
Fex-3制备步骤为:
(1)10.00g化合物1和16.50g联硼酸频哪醇酯溶于60mL 1,4-二氧六环溶液,加入12.26g醋酸钾,1.83g PdCl2(dppf),氮气保护,85℃反应4小时后将反应物倒入250mL水中,用50mL乙酸乙酯萃取三次,合并有机相,用100mL饱和氯化铵溶液洗涤两次,再用100mL饱和食盐水洗涤一次,加入无水硫酸钠干燥,浓缩后得到18.00g棕色胶状粗产品,硅胶柱色谱分离得到6.50g化合物2粗产品, 加入10mL石油醚,抽滤并收集滤饼旋干得到5.60g化合物2,为白色固体,产率45.34%;
(2)10.00g化合物3,12.79g丙烯酸甲酯,20.9mL三乙胺,222.28mg Pd(OAc)2和519mg三苯基膦,在50mLN,N-二甲酰胺体系中氮气保护反应18小时, 将反应液倒入250mL水中,用50mL乙酸乙酯萃取三次,合并有机相,用100mL饱和氯化铵溶液洗涤两次,无水硫酸钠干燥,减压旋干溶剂,硅胶柱色谱分离,得到5.20g化合物4,为黄色固体,产率50.7%;
(3)5.20g化合物4,8.20g锌粉和6.71g氯化铵在40mL甲醇与10mL水的混合体系中反应3小时, 用饱和碳酸氢钠溶液调pH至8,抽滤,旋干滤液,用50mL乙酸乙酯萃取三次,合并有机相,用100mL饱和食盐水洗涤,无水硫酸钠干燥,抽滤,旋干溶液,得到4.25g化合物5粗品,为黄色固体,产率94.53%;
(4)2.50g化合物5和2.61g 4-溴苯甲醛溶于30mL二氯甲烷中,加入42.36mg乙酸,20℃反应4小时后加入4.49g NaBH(OAc)3,10-20℃反应16小时, 反应液依次用50mL饱和碳酸氢钠溶液、50mL饱和氯化铵溶液和50mL饱和食盐水洗涤,有机相用无水硫酸钠干燥,过滤出去硫酸钠,有机相浓缩旋干,硅胶柱色谱分离得到3.60g化合物6,产率73.7%;
(5)3.50g化合物6,2.75g化合物2,369.85mg PdCl2(dppf),3.21g碳酸钠溶于40mL1,4-二氧六环与10mL水的混合体系中,氮气保护,85℃反应16小时后将反应液倒入80mL水中,用30mL乙酸乙酯萃取三次,合并有机相,依次用50mL饱和氯化铵溶液和50mL饱和食盐水洗涤,无水硫酸钠干燥,抽滤旋干,硅胶柱色谱分离,得到2.40g化合物7,为黄色油状,产率61.43%;
(6)2.40g化合物7,2.62mL三乙胺,75.87mg 4-二甲氨基吡啶溶于30mL二氯甲烷中,10-20℃加入1.92g 6-溴-2-萘酰氯,20℃下搅拌反应16小时,硅胶柱分离,得到2.20g化合物8,为黄色固体,产率57.18%;
(7)2.20g化合物8,8.88mL甲胺四氢呋喃溶液,40.00mg Pd(OAc)2,940.90mg碳酸钠溶于50mL 1,4-二氧六环中,氮气保护,100℃下反应16小时后将反应液倒入80mL水中,用30mL乙酸乙酯萃取三次,合并有机相,依次用50mL饱和氯化铵溶液和50mL饱和食盐水洗涤,无水硫酸钠干燥,硅胶柱色谱分离得到棕色油状粗产品900.00mg,使用制备薄层色谱分离得到化合物300.00mg Fex-3,产率14.83%,产物为淡黄色固体;
Fex-4制备步骤为:
(1)10.00g化合物1和16.50g联硼酸频哪醇酯溶于60mL 1,4-二氧六环溶液,加入12.26g醋酸钾,1.83g PdCl2(dppf),氮气保护,85℃反应4小时后将反应物倒入250mL水中,用50mL乙酸乙酯萃取三次,合并有机相,用100mL饱和氯化铵溶液洗涤两次,再用100mL饱和食盐水洗涤一次,加入无水硫酸钠干燥,浓缩后得到18.00g棕色胶状粗产品,硅胶柱色谱分离得到6.50g化合物2粗产品, 加入10mL石油醚,抽滤并收集滤饼旋干得到5.60g化合物2,为白色固体,产率45.34%;
(2)10.00g化合物3,12.79g丙烯酸甲酯,20.9mL三乙胺,222.28mg Pd(OAc)2和519mg三苯基膦,在50mLN,N-二甲酰胺体系中氮气保护反应18小时, 将反应液倒入250 mL水中,用50mL乙酸乙酯萃取三次,合并有机相,用100mL饱和氯化铵溶液洗涤两次,无水硫酸钠干燥,减压旋干溶剂,硅胶柱色谱分离,得到5.20g化合物4,为黄色固体,产率50.7%;
(3)5.20g化合物4,8.20g锌粉和6.71g氯化铵在40mL甲醇与10mL水的混合体系中反应3小时, 用饱和碳酸氢钠溶液调pH至8,抽滤,旋干滤液,用50mL乙酸乙酯萃取三次,合并有机相,用100mL饱和食盐水洗涤,无水硫酸钠干燥,抽滤,旋干溶液,得到4.25g化合物5粗品,为黄色固体,产率94.53%;
(4)2.50g化合物5和2.61g 4-溴苯甲醛溶于30mL二氯甲烷中,加入42.36mg乙酸,20℃反应4小时后加入4.49g NaBH(OAc)3,10-20℃反应16小时, 反应液依次用50mL饱和碳酸氢钠溶液、50mL饱和氯化铵溶液和50mL饱和食盐水洗涤,有机相用无水硫酸钠干燥,过滤出去硫酸钠,有机相浓缩旋干,硅胶柱色谱分离得到3.60g化合物6,产率73.7%;
(5)3.50g化合物6,2.75g化合物2,369.85mg PdCl2(dppf),3.21g碳酸钠溶于40mL1,4-二氧六环与10mL水的混合体系中,氮气保护,85℃反应16小时后将反应液倒入80mL水中,用30mL乙酸乙酯萃取三次,合并有机相,依次用50mL饱和氯化铵溶液和50mL饱和食盐水洗涤,无水硫酸钠干燥,抽滤旋干,硅胶柱色谱分离,得到2.40g化合物7,为黄色油状,产率61.43%;
(6)2.40g化合物7,2.62mL三乙胺,75.87mg 4-二甲氨基吡啶溶于30mL二氯甲烷中,10-20℃加入1.92g 6-溴-2-萘酰氯,20℃下搅拌反应16小时,硅胶柱分离,得到2.20g化合物8,为黄色固体,产率57.18%;
(7)2.20g化合物8,8.88mL二甲胺四氢呋喃溶液,40.00mg Pd(OAc)2,940.90mg碳酸钠溶于50mL 1,4-二氧六环中,氮气保护,100℃下反应16小时后将反应液倒入80mL水中,用30mL乙酸乙酯萃取三次,合并有机相,依次用50mL饱和氯化铵溶液和50mL饱和食盐水洗涤,无水硫酸钠干燥,使用制备薄层色谱分离得到化合物933.62mg Fex-4,产率45.11%,产物为淡黄色固体。
2.如权利要求1所述的制备方法得到的化合物Fex-3和化合物Fex-4的应用,其特征在于:激动FXR和其下游靶基因SHP、BSEP和CYP7A1。
3.如权利要求1所述的制备方法得到的化合物Fex-3和化合物Fex-4的应用,其特征在于:用于治疗胰岛素抵抗和肥胖。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610578225.4A CN106518708B (zh) | 2016-07-18 | 2016-07-18 | 新型fxr激动剂的合成和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610578225.4A CN106518708B (zh) | 2016-07-18 | 2016-07-18 | 新型fxr激动剂的合成和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106518708A CN106518708A (zh) | 2017-03-22 |
CN106518708B true CN106518708B (zh) | 2018-02-16 |
Family
ID=58343529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610578225.4A Expired - Fee Related CN106518708B (zh) | 2016-07-18 | 2016-07-18 | 新型fxr激动剂的合成和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106518708B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727480B (zh) * | 2016-12-02 | 2019-05-31 | 中国药科大学 | Fex-3在制备抗肥胖症药物中的应用 |
CN110540955B (zh) * | 2019-08-28 | 2021-09-17 | 北京协同创新研究院 | 一种提高分化细胞中nrob2基因表达量的方法 |
CN112315952A (zh) * | 2020-11-26 | 2021-02-05 | 中国药科大学 | Fex-3在制备抗非酒精脂肪性肝炎(NASH)中的用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104513213A (zh) * | 2013-09-28 | 2015-04-15 | 山东亨利医药科技有限责任公司 | Fxr激动剂 |
-
2016
- 2016-07-18 CN CN201610578225.4A patent/CN106518708B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN106518708A (zh) | 2017-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104672290B (zh) | 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途 | |
CN106518708B (zh) | 新型fxr激动剂的合成和应用 | |
CN101658528B (zh) | 玉米须多糖在制备治疗高血脂症的药物中的应用 | |
CN107428792A (zh) | 用于治疗乙型肝炎病毒的磷酰胺 | |
CN102731492B (zh) | 环己烷类衍生物、其制备方法及其在医药上的应用 | |
CN104586860A (zh) | 达玛烷型三萜衍生物的用途 | |
CN101704763A (zh) | 阿戈美拉汀i型晶体的制备方法 | |
CN107176933A (zh) | 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂 | |
CN101012211B (zh) | 取代的穿心莲内酯衍生物、制备方法及其药物组合物 | |
CN103275051B (zh) | 一种7,3’,4’-三羟基黄酮衍生物及其在制备治疗肝癌药物中的应用 | |
CN113336765B (zh) | 一种莪术醇酯化物、制备方法及其在治疗结直肠癌药物中的应用 | |
CN107721982A (zh) | 一种抗肥胖症化合物及其制备方法和应用 | |
CN105348354A (zh) | 一类鹅去氧胆酸类化合物及其制备方法和用途 | |
CN106674242A (zh) | 一种具有抗肿瘤活性的莪术醇衍生物及其制备方法和应用 | |
CN103254212B (zh) | 番荔枝内酯衍生物及其制备方法和用途 | |
CN102952105A (zh) | 一类霉酚酸衍生物、其制备方法和用途 | |
CN101541780A (zh) | 贝特羧酸酯类化合物及其制备方法和用途 | |
CN105837592B (zh) | 间苯三酚骈松香烷二萜类化合物及其制备方法和药物用途 | |
CN104803863B (zh) | 阳离子类脂化合物及其制备方法 | |
CN105434338A (zh) | 一种银杏内酯b氯化钠注射液及其制备方法 | |
CN104860919B (zh) | 含哌啶的苯并咪唑衍生物及其制备方法和用途 | |
CN104873976A (zh) | 一类阳离子类脂化合物的应用 | |
CN108164528A (zh) | 一种酰胺类衍生物及其在高血压、高血脂和动脉粥样硬化中的应用 | |
CN110063960A (zh) | 3-氢化松苓酸b氰甲酯的制药用途 | |
CN111303195B (zh) | 一类含硼小分子化合物、其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180216 |